Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
24.81
-2.18 (-8.06%)
At close: Aug 27, 2025, 4:00 PM
25.10
+0.30 (1.19%)
Pre-market: Aug 28, 2025, 5:13 AM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
18.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SMMT News
- 15 hours ago - Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst - Benzinga
- 13 days ago - Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 - Business Wire
- 16 days ago - Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 - Business Wire
- 6 weeks ago - SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 7 weeks ago - Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain - Seeking Alpha
- 2 months ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire
- 2 months ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire